Number of pay-for-delay deals remains low, says FTC
07-12-2020
Seventh Circuit urged to review AbbVie antitrust ruling
15-10-2020
AG advises CJEU to uphold €94 million pay-for-delay fine
05-06-2020
madamF / Shutterstock.com
The European Commission has fined Teva and its subsidiary Cephalon €60.5 million ($72 million) for agreeing to delay a cheaper generic version of sleep disorder drug modafinil.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
European Commission, Teva, Cephalon, generics, pay-for-delay, competition law, patents, modafinil, fines
